2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 222

Role of Synovial Biopsy in Diagnosis of Crystal Arthropathies
Abstract Number: 223

Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York
Abstract Number: 224

Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study
Abstract Number: 225

Patterns of Joint Involvement in Gout Flares
Abstract Number: 226

Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA
Abstract Number: 227

Inadequately Treated Chronic Gout As the Main Reason for Primary Gout Admission in an Urban Adult Population: Results of a Retrospective Cohort Study
Abstract Number: 228

Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study
Abstract Number: 229

Relationship Between Patient and Disease Factors and Severity of Gout in a Real-World Population
Abstract Number: 230

A Survey of Knowledge of Optimal Gout Management in an Academic Primary Care Setting
Abstract Number: 231

Impact of an Educational Program for the Management of Gout Directed to Primary Care Physicians
Abstract Number: 232

Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Abstract Number: 233

New Cardiovascular Risk Factors Screening in Patients with Gout
Abstract Number: 234

Coexistent Gout and Rheumatoid Arthritis: Comparison of Comorbidity, Autoantibodies, Disease Measures, and All-Cause Mortality
Abstract Number: 235

Concurrence of Rheumatoid Arthritis and Calcium Pyrophosphate Deposition Disease: Description of a Cohort
Abstract Number: 236

Intrathoracic Manifestations of IgG4-Related Disease: Findings in a Cohort Study from North America

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].